The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

In late 2021, Pfizer (PFE-0.21%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine. It followed that success with the launch ...

No doubt, Pfizer (PFE) is one of 2021’s out-and-out success stories. The pharma giant has posted year-to-date gains of a remarkable 72%, and the company – and investors – have Covid-19 to ...

High Yielding Pfizer Looks Bullish (Technical Analysis) Jul. 28, 2024 2:52 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 25 Comments 7 Likes Walter Zelezniak Jr ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...